More than 110 drugs, capable of penetrating this elusive barrier are currently being evaluated for the treatment of CNS disorders; there are nearly 35 technology platforms for the development of BBB p

The concept of BBB penetration is anticipated to bring about a paradigm shift in modern healthcare. In fact, experts believe that there is an important relationship between the recent pandemic of Coronavirus disease (COVID-19) and cerebrovascular system, presenting commercial opportunities for players engaged in the development of BBB penetrating drugs.

 

• An overview of the overall landscape of BBB penetration technologies, featuring an in-depth analysis of the technologies based on a number of parameters, such as status of development (developed and under development), affiliated approach, type of compatible pharmacological molecule(s) crossing the BBB (small molecule and biologic), target receptor(s), target disease indication(s), patent availability, and licensing activity. In addition, it presents a detailed assessment of BBB technology developers and analyses based on parameters, such as year of establishment, company size, and location of headquarters.
• A detailed assessment of the current market landscape of BBB penetrant drugs (based on the abovementioned technologies), providing information on drug developer(s) (such as year of establishment, company size, and location of headquarters), phase of development (clinical, preclinical, and discovery stage), type of molecule (small molecule and biologic), affiliated BBB penetration technology, route of administration (oral, intravenous, transmucosal and others), target disease indication(s), key therapeutic area(s), and information on special drug designation (if any).
• Identification of contemporary market trends, depicted using three schematic representations, which include [A] a tree map representation of the various industry players involved in the development of BBB penetrant drugs, distributed on the basis of the target disease indication(s) of pipeline candidates and size of the companies (small, mid-sized and large companies), [B] a bubble analysis comparing the leading players engaged in the development of BBB penetrant drugs, on the basis of parameters such as pipeline strength (based on the number of drug candidates developed by a particular company, across different phases of development), number of target disease indication(s) and the size of the developer company, and [C] an informative heptagon representation, highlighting the distribution of BBB penetrant drugs across popular target disease indication(s) (based on the number of drug candidates across each target disease indication).

To order this 400+ page report, which features 145+ figures and 205+ tables, please visit this link

 

The USD 940 million (by 2030) financial opportunity within the BBB market has been analyzed across the following segments:

• Type of Payment Model Adopted

• Upfront payments
• Milestone payments

 

• Type of Molecule
• Small Molecules
• Biologics

 

• Target Disease Indication

• Brain Metastases in Breast Cancer
• Glioblastoma Multiforme
• Hunter Syndrome
• Hurler Syndrome

 

• Leading Technology Platforms

• G®-Technology
• J-Brain Cargo® Technology
• LRP-1 Technology
• Trojan Horse Technology

 

• Leading Drug Developers

• 2-BBB
• Angiochem
• ArmaGen
• JCR Pharmaceuticals

 

• Key Geographical Regions
• North America
• Europe
• Asia-Pacific

 

 

The Blood-Brain Barrier (BBB) Market (2nd Edition), 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics report features the following companies, which we identified to be key players in this domain:

• Angiochem
• ArmaGen
• BioArctic
• Cyclenium Pharma
• Denali Therapeutics
• ICB International
• Iproteos
• JCR Pharmaceuticals
• Lauren Sciences
• Medesis Pharma
• Ossianix
• Vect-Horus

 

Table of Contents

 

1. Preface

2. Executive Summary

3. Introduction
 

4. Market Landscape: Non-Invasive BBB Penetration
 

5. Market Landscape: BBB Penetrating Drugs
 

6. Company Profiles
 

7. Technology Competitiveness Analysis
 

8. Non-Invasive BBB Penetration Technologies: Popular Approaches

9. Partnerships and Collaborations
 

10. Analysis of Recent Licensing Agreements
 

11. Funding and Investment Analysis
 

12. Patent Analysis
 

13. Drug Development Strategy Analysis
 

14. Market Potential of Key Neurological Disorders

 

15. Likely Partner Analysis

 

16. Market Forecast

 

17. Conclusion

 

18. Executive Insights

 

19. Appendix 1: Tabulated Data

 

20. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/blood-brain-barrier-drug-delivery/310.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]